Teva Reports Positive Phase 2a Results for Anti-IL-15 Antibody in Celiac Disease

Teva Pharmaceutical Industries announced positive topline results from a Phase 2a study of TEV '408, an investigational anti-interleukin-15 monoclonal antibody, for celiac disease. The study met its primary endpoint, demonstrating statistically significant and clinically meaningful prevention of gluten-induced intestinal damage, and the drug was well-tolerated.